T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$7.49B |
| 2 |
Micron Technology
MU
|
+$6.62B |
| 3 |
Lam Research
LRCX
|
+$3.45B |
| 4 |
Applied Materials
AMAT
|
+$3.03B |
| 5 |
Advanced Micro Devices
AMD
|
+$2.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1B |
| 2 |
Apple
AAPL
|
+$11.6B |
| 3 |
Amazon
AMZN
|
+$3.54B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.07B |
| 5 |
Keysight
KEYS
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.73% |
| 2 | Healthcare | 11.3% |
| 3 | Financials | 10.32% |
| 4 | Communication Services | 9.66% |
| 5 | Industrials | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SPYM
2776
State Street SPDR Portfolio S&P 500 ETF
SPYM
$176B
| $351K | ﹤0.01% |
3,991
+106
| +3% | +$9.04K |
|
2777
Colony Bankcorp
CBAN
$439M
| $350K | ﹤0.01% |
17,399
+2,961
| +21% | +$59.8K |
|
2778
Hertz
HTZ
$620M
| $350K | ﹤0.01% |
154,263
+17,130
| +12% | +$93.5K |
|
2779
Tiptree Inc
TIPT
$639M
| $350K | ﹤0.01% |
19,496
+620
| +3% | +$10.7K |
|
2780
HighPeak Energy
HPK
$956M
| $348K | ﹤0.01% |
49,705
| – | – |
|
2781
RBB Bancorp
RBB
$450M
| $347K | ﹤0.01% |
12,651
+1,969
| +18% | +$47.2K |
|
2782
Petco
WOOF
$650M
| $347K | ﹤0.01% |
127,432
+30,266
| +31% | +$84K |
|
2783
Alto Ingredients
ALTO
$289M
| $346K | ﹤0.01% |
+60,607
| New | +$309K |
|
2784
Bank of Marin Bancorp
BMRC
$452M
| $346K | ﹤0.01% |
12,458
+2,342
| +23% | +$61.1K |
|
2785
Contango Silver & Gold Inc
CTGO
$620M
| $346K | ﹤0.01% |
21,891
+6,916
| +46% | +$142K |
|
2786
Neuropace
NPCE
$483M
| $346K | ﹤0.01% |
21,764
+4,456
| +26% | +$71.7K |
|
2787
Fulcrum Therapeutics
FULC
$285M
| $345K | ﹤0.01% |
94,235
+14,066
| +18% | +$85.6K |
|
2788
Medifast
MED
$136M
| $344K | ﹤0.01% |
32,378
+5,673
| +21% | +$65.4K |
|
2789
Mativ Holdings
MATV
$658M
| $343K | ﹤0.01% |
45,228
+5,714
| +14% | +$49.2K |
|
2790
Monopar Therapeutics
MNPR
$572M
| $343K | ﹤0.01% |
3,699
-44,003
| -92% | -$2.72M |
|
2791
Capital Bancorp
CBNK
$587M
| $342K | ﹤0.01% |
9,737
+245
| +3% | +$7.85K |
|
2792
RGC Resources
RGCO
$222M
| $342K | ﹤0.01% |
14,300
| – | – |
|
2793
Farmers & Merchants Bancorp
FMAO
$481M
| $341K | ﹤0.01% |
11,126
+2,184
| +24% | +$60.3K |
|
2794
M-tron Industries
MPTI
$322M
| $341K | ﹤0.01% |
+3,433
| New | +$273K |
|
2795
Enanta Pharmaceuticals
ENTA
$346M
| $340K | ﹤0.01% |
23,297
+4,593
| +25% | +$61.7K |
|
2796
Ovid Therapeutics
OVID
$469M
| $339K | ﹤0.01% |
+125,725
| New | +$324K |
|
|
FBRX
2797
DELISTED
Forte Biosciences
FBRX
| $338K | ﹤0.01% |
+15,900
| New | +$377K |
|
2798
One Stop Systems
OSS
$231M
| $336K | ﹤0.01% |
+18,450
| New | +$257K |
|
|
STLN
2799
Starling Oncology
STLN
$679M
| $336K | ﹤0.01% |
61,750
+13,479
| +28% | +$56.6K |
|
2800
Citizens & Northern Corp
CZNC
$461M
| $335K | ﹤0.01% |
14,356
+661
| +5% | +$14.6K |
|
Similar funds
T. Rowe Price Associates's Q2 2026 Portfolio in Review
As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
- T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
- T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
- T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
- T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
- T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.